Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Lung Cancer

• Publication date

  2004-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.LUNGCAN.2003.09.026PMID 15013588
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiac dysfunction in the trastuzumab clinical trials experience.

  2002cited by this paper
• Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results.

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C), and trastuzumab (T) in HER-2/neu (+)advanced non-small cell lung cancer (nsclc): early analysis of e2598

  2001cited by this paper
• Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.

  2001cited by this paper
• Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results.

  2001cited by this paper
• Effect of HER2/neu expression on survival in non-small-cell lung cancer.

  2001cited by this paper
• Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.

  2001cited by this paper
• Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.

  2000cited by this paper
• Monitoring Therapy by Serum HER-2/Neu

  2000cited by this paper
• Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.

  1999cited by this paper
• Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.

  1999cited by this paper
• The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients.

  1998cited by this paper
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

  1998cited by this paper
• Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

  1997cited by this paper
• Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections.

  1996cited by this paper
• Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma.

  1995cited by this paper
• Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.

  1995cited by this paper
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

  1995cited by this paper
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

  1995cited by this paper
• c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.

  1994cited by this paper
• Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma.

  1994cited by this paper
• Detection of increased amounts of the extracellular domain of the c‐erbB‐2 oncoprotein in serum during pulmonary carcinogenesis in humans

  1994cited by this paper
• C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.

  1994cited by this paper
• Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody.

  1993cited by this paper
• Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.

  1993cited by this paper
• Biological consequences of overexpression of a transfected c-erbB-2 gene in immortalized human bronchial epithelial cells.

  1993cited by this paper
• Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.

  1992cited by this paper
• Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.

  1992cited by this paper
• Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines.

  1992cited by this paper
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992cited by this paper
• Overexpression of the c‐erbB‐2/neu–encoded p185 protein in primary lung cancer

  1992cited by this paper
• Selection of monoclonal antibodies which induce internalization and phosphorylation of P185HER2 and growth inhibition of cells with HER2/neu gene amplification

  1991cited by this paper
• Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung.

  1990cited by this paper
• Practical statistics for medical research

  1990cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer.

  1989cited by this paper
• Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

  1988cited by this paper
• Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo.

  1988cited by this paper
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

  1977cited by this paper
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

  1976cited by this paper
• [Cancer of the lung].

  1952cited by this paper

• Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies

  2025cites this paper
• HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top

  2025cites this paper
• The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer

  2025cites this paper
• Light on the horizon for HER2 overexpressing non-small cell lung cancer?

  2025cites this paper
• Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial.

  2025cites this paper
• Emerging Biomarkers in Non–small Cell Lung Cancer

  2025cites this paper
• Research Progress in Clinical Therapeutic Efficacy and Safety of HER2-Positive Non-Small Cell Lung Cancer

  2024cites this paper
• Real‐World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)‐Mutant Metastatic Non‐Small Cell Lung Cancer, From a US‐Based Clinico‐Genomic Database

  2024cites this paper
• Targeted therapy for lung cancer: Beyond EGFR and ALK

  2023cites this paper
• Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy

  2023cites this paper
• Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients

  2023cites this paper
• HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies

  2023cites this paper
• Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.

  2023cites this paper
• Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer.

  2023cites this paper
• A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers

  2023cites this paper
• Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis

  2022cites this paper
• Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives

  2022cites this paper
• HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies

  2022cites this paper
• NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease

  2022cites this paper
• Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy.

  2021cites this paper
• Efficacy of targeted therapy in patients with HER2‐positive non‐small cell lung cancer: A systematic review and meta‐analysis

  2021cites this paper
• HER-2 as a Prognostic and Predictive Biomarker in Cancer

  2021cites this paper
• Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations

  2021cites this paper
• A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers

  2021cites this paper
• Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy

  2021cites this paper
• Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives

  2020cites this paper
• The efficacy of ado-trastuzumab emtansine in patients with ERBB2-aberrant non-small cell lung cancer: a systematic review

  2020cites this paper
• Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.

  2020cites this paper
• Corporate Medical Policy

  2020cites this paper
• Targeting HER2 Alterations in Non-Small-Cell Lung Cancer: A Comprehensive Review.

  2020cites this paper
• Targeted Therapy for Non-Small Cell Lung Cancer

  2020cites this paper
• Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy.

  2020cites this paper
• New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

  2020cites this paper
• FHITlow/pHER2high signature in non‐small cell lung cancer is predictive of anti‐HER2 molecule efficacy

  2020cites this paper
• A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).

  2019cites this paper
• Monoclonal Antibodies: Past, Present and Future.

  2019cites this paper
• Targeting HER2 in Lung Cancer

  2019cites this paper
• Targeted Therapies for Lung Cancer

  2019cites this paper
• Clinical Trial Outcomes: What Matters to Patients.

  2019cites this paper
• Personalized therapy for lung cancer: striking a moving target.

  2018cites this paper
• Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment

  2018cites this paper
• Concordance analysis between HER2 immunohistochemistry and in situ hybridization in non-small cell lung cancer

  2018cites this paper
• ERBB2‐Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies

  2017cites this paper
• Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non–Small‐Cell Lung Cancer: Study Protocol

  2017cites this paper
• Anti-Tumour Treatment Evolution of anti-HER 2 therapies for cancer treatment

  2017influential citation
• Current Trial Report Trastuzumab Emtansine in HER2þ Recurrent Metastatic NoneSmall-Cell Lung Cancer: Study Protocol

  2017cites this paper
• Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

  2017cites this paper
• Evolution of anti-HER2 therapies for cancer treatment.

  2017cites this paper
• Changing paradigm in treatment of lung cancer

  2016cites this paper
• Emerging targeted therapies in non-small cell lung cancer

  2016cites this paper
• Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough

  2015cites this paper
• Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors

  2015cites this paper
• Molecular landscape of non-squamous, non-small cell carcinoma of the lung

  2015cites this paper
• HER2在NSCLC中的作用

  2015cites this paper
• From Uniplex to Multiplex Molecular Profiling in Advanced Non–Small Cell Lung Carcinoma

  2015cites this paper
• Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK

  2015cites this paper
• HER2: An emerging biomarker in non-breast and non-gastric cancers

  2015cites this paper
• Strategies in Patients with Other Molecular Alterations

  2015cites this paper
• Targeting HER2 in the treatment of non-small cell lung cancer.

  2015cites this paper
• Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.

  2015cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations

  2014cites this paper
• Review of the current targeted therapies for non-small-cell lung cancer.

  2014cites this paper
• Association of high LDH and low glucose levels in pleural space with HER2 expression in non-small cell lung cancer.

  2014influential citation
• NSCLC and HER2: Between Lights and Shadows

  2014cites this paper
• Clinical Trial Outcomes part of HER 2 / neu : an increasingly important therapeutic target . Part 3 : clinical applications and investigations

  2014cites this paper
• Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer

  2014cites this paper
• HER2 in solid tumors: more than 10 years under the microscope; where are we now?

  2014cites this paper
• HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.

  2014cites this paper
• Targeted therapy in NSCLC driven by HER2 insertions.

  2014cites this paper
• Rare mutations in non-small-cell lung cancer.

  2013cites this paper
• Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment

  2013influential citation
• Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma

  2013cites this paper
• New targetable oncogenes in non-small-cell lung cancer.

  2013cites this paper
• Pharmacogenetic study of Fc gamma receptor and HER2 genes in breast cancer

  2013cites this paper
• Lung cancer and genitourinary cancers

  2013cites this paper
• Paradigme de la prise en charge du cancer bronchique et de celle des autres cancers : homologies, analogies, dissemblances

  2013cites this paper
• HER2 and lung cancer

  2013cites this paper
• Circulating levels of HER-2/neu oncoprotein in breast cancer

  2012cites this paper
• Les mutations de HER2 dans les cancers bronchiques : caractéristiques et perspectives thérapeutiques

  2012cites this paper
• p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer

  2012cites this paper
• Primary treatment of advanced non-small-cell lung cancer: role of monoclonal antibodies

  2012cites this paper
• Monoclonal Antibodies: An Emerging Class of Therapeutics in Non Small Cell Lung Cancer

  2012cites this paper
• Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung

  2012cites this paper
• AKC İĞ ER KANSER İNDE İNTERFAZ FISH ANAL İZİ İLE KROMOZOMAL ANÖPLO İDİLER İN SAPTANMASI

  2012cites this paper
• Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

  2010cites this paper
• Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors

  2010cites this paper
• Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab.

  2010cites this paper
• The Effect of Health Care Expenditures on Survival in Locally Advanced and Metastatic Non Small Cell Lung Cancer

  2009cites this paper
• Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies

  2009cites this paper
• Imaging and biodistribution of Her2/neu expression in non‐small cell lung cancer xenografts with 64Cu‐labeled trastuzumab PET

  2009cites this paper
• Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer

  2009cites this paper
• Biological therapy of lung cancer

  2009cites this paper
• Targeted therapies in lung cancer.

  2009cites this paper
• Monoclonal antibody therapy

  2009cites this paper
• Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells.

  2009cites this paper
• Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen

  2009cites this paper
• [Targeting HER pathway in head and neck and thoracic cancers].

  2009cites this paper
• Recent advances of novel targeted therapy in non-small cell lung cancer

  2009cites this paper
• Somatic pharmacogenomics in cancer

  2008cites this paper
• Multitargeted inhibitors in lung cancer: new clinical data.

  2008cites this paper